Literature DB >> 7905093

Changes in prostate cancer incidence and treatment in USA.

G L Lu-Yao1, E R Greenberg.   

Abstract

We examined time trends and geographical variations in the detection and treatment of prostate cancer in USA, based on information from white men aged 50 to 79 who resided in areas covered by the Surveillance, Epidemiology, and End Results (SEER) program of the United States National Cancer Institute. Prostate-cancer incidence and treatment rates were determined for the 9 population-based cancer registries which participate in the SEER program. Prostate-cancer mortality rates were assessed from data compiled by the National Center for Health Statistics. Prostate cancer incidence rates increased by 6.4% per year between 1983 and 1989. The increase appeared to be due to detection of early-stage disease; there was no increase in the incidence rate of metastatic cancer. Incidence rates varied widely among the SEER program areas: in 1989 from 267.9 per 100,000 in Connecticut to 606.8 in Seattle. Radical prostatectomy rates more than tripled between 1983 and 1989 in the SEER areas as a whole. Among men aged 70-79, the rate of prostatectomy increased by nearly 35% per year. There was a five-fold variation among SEER areas in radical prostatectomy rates in 1989, with a low of 43.4 per 100,000 in Connecticut and a high of 224.4 in Seattle. Prostate cancer mortality rates did not increase during the period of study; there was little variation among areas in prostate-cancer mortality rates, and no apparent correlation between the incidence and mortality rates for an area. Increases in rates of prostate cancer incidence and prostate surgery have occurred in the United States without clear evidence that screening and prostectomy are effective in reducing mortality. Moreover, much of the growth in incidence and radical prostatectomy rates has occurred among older men, who appear least likely to benefit from early detection and surgery of occult prostate cancer.

Entities:  

Mesh:

Year:  1994        PMID: 7905093     DOI: 10.1016/s0140-6736(94)91109-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  29 in total

1.  Localised prostate cancer: can we do better? There have been some advances in local control, but little impact on survival.

Authors:  T Prior; J Waxman
Journal:  BMJ       Date:  2000-01-08

2.  Patterns of prostate cancer treatment by clinical stage and age.

Authors:  D Meltzer; B Egleston; I Abdalla
Journal:  Am J Public Health       Date:  2001-01       Impact factor: 9.308

3.  Bcl-2 immunoreactivity in prostate tumorigenesis in relation to prostatic intraepithelial neoplasia, grade, hormonal status, metastatic growth and survival.

Authors:  P Stattin; J E Damber; L Karlberg; H Nordgren; A Bergh
Journal:  Urol Res       Date:  1996

4.  Variation in chemotherapy utilization in ovarian cancer: the relative contribution of geography.

Authors:  Daniel Polsky; Katrina A Armstrong; Thomas C Randall; Richard N Ross; Orit Even-Shoshan; Paul R Rosenbaum; Jeffrey H Silber
Journal:  Health Serv Res       Date:  2006-12       Impact factor: 3.402

5.  Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging.

Authors:  Stefano Cirillo; Massimo Petracchini; Lorenza Scotti; Teresa Gallo; Annalisa Macera; Maria Cristina Bona; Cinzia Ortega; Pietro Gabriele; Daniele Regge
Journal:  Eur Radiol       Date:  2008-09-30       Impact factor: 5.315

6.  Screening, treatment, and prostate cancer mortality in the Seattle area and Connecticut: fifteen-year follow-up.

Authors:  Grace Lu-Yao; Peter C Albertsen; Janet L Stanford; Therese A Stukel; Elizabeth Walker-Corkery; Michael J Barry
Journal:  J Gen Intern Med       Date:  2008-09-16       Impact factor: 5.128

7.  Detection of prostate cancer.

Authors:  F H Schröder
Journal:  BMJ       Date:  1995-01-21

Review 8.  Screening for prostate cancer. Implications for drug therapy.

Authors:  R H Harwood
Journal:  Drugs Aging       Date:  1995-05       Impact factor: 3.923

9.  The changing pattern of prostate cancer in Nigerians: current status in the southeastern states.

Authors:  Paul D Ekwere; S N Egbe
Journal:  J Natl Med Assoc       Date:  2002-07       Impact factor: 1.798

10.  Prostate cancer screening (United States).

Authors:  J W Waterbor; A J Bueschen
Journal:  Cancer Causes Control       Date:  1995-05       Impact factor: 2.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.